Lipodystrophy - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 51
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: LBA8D3050A7EN
Leaflet:

Download PDF Leaflet

Lipodystrophy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Lipodystrophy - Pipeline Review, H2 2016’, provides an overview of the Lipodystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
  • The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lipodystrophy
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Lipodystrophy Overview
Therapeutics Development
Pipeline Products for Lipodystrophy - Overview
Lipodystrophy - Therapeutics under Development by Companies
Lipodystrophy - Pipeline Products Glance
Late Stage Products
Early Stage Products
Lipodystrophy - Products under Development by Companies
Lipodystrophy - Companies Involved in Therapeutics Development
Aegerion Pharmaceuticals, Inc.
Akcea Therapeutics Inc
Ambrx, Inc.
Amunix Operating Inc.
Bolder Biotechnology, Inc.
Lipodystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMX-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARX-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volanesorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lipodystrophy - Product Development Milestones
Featured News & Press Releases
Jul 28, 2016: Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy
Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes
May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy
Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy
Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy
Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy
Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy
Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy
Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Dec 16, 2008: Bolder BioTechnology Receives $1.9 million NIH Grant To Continue Development of Long-Acting Growth Hormone Product BBT-031
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Lipodystrophy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Lipodystrophy - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2016
Lipodystrophy - Pipeline by Akcea Therapeutics Inc, H2 2016
Lipodystrophy - Pipeline by Ambrx, Inc., H2 2016
Lipodystrophy - Pipeline by Amunix Operating Inc. , H2 2016
Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

LIST OF FIGURES

Number of Products under Development for Lipodystrophy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Lipodystrophy - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 63 pages
Myocardial Fibrosis - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 77 pages
Fibrosarcoma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 64 pages
Warts - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 99 pages

Ask Your Question

Lipodystrophy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: